Movex® 100 mg Tablet: Each film-coated tablet contains Aceclofenac BP 100 mg.
Movex® SR 200 mg Tablet: Each sustained release tablet contains Aceclofenac BP 200 mg.
Aceclofenac is a nonsteroidal anti-inflammatory agent that exhibits analgesic and anti-inflammatory actions.
Mode of action:
It inhibits prostaglandin synthesis by inhibiting cyclo-oxygenase enzyme. It also stimulates cartilage (glycosaminoglycan) synthesis.
Pharmacokinetics:
After oral administration, aceclofenac is rapidly and completely absorbed as unchanged drug. Peak plasma concentration is reached approximately within 1.25 to 3 hours after administration. Aceclofenac penetrates into the synovial fluid, where the concentrations reach approximately 57% of those in plasma. The mean plasma elimination half-life is around 4 hours. Aceclofenac is highly protein bound (>99%). 4-hydroxy-aceclofenac is the main metabolite detected in plasma. Approximately two-thirds of the administered dose is excreted via the urine, mainly as hydroxymetabolites.
Aceclofenac is indicated for the relief of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis.
Aceclofenac may inhibit the activity of diuretics. Anticoagulants: Like other NSAIDs, aceclofenac may enhance the activity of anticoagulants. Aceclofenac, like other NSAIDs, may increase plasma concentrations of lithium and digoxin. Concomitant therapy with aspirin, other NSAIDs and steroids may increase the frequency of side effects.
Over dosage:
There is no human data available on the consequences of aceclofenac overdosage. After overdosage, following therapeutic measures to be taken. Absorption should be prevented as soon as possible by means of gastric lavage and treatment with activated charcoal. Supportive and symptomatic treatment should be given for complications.
USFDA pregnancy category C. There is no established data regarding uses in lactating mother. It should not be used in pregnancy & lactation until emergency.
Aceclofenac should be administered with caution to patients with symptoms indicative of gastrointestinal disorders, with a history of peptic ulceration, ulcerative colitis, crohn’s disease, hepatic porphyria, and coagulation disorders. Patients suffering from severe hepatic impairment must be monitored.
Store in a cool and dry place, protected from light.